Valproic acid radiosensitizes anaplastic thyroid cells through a decrease of the DNA damage repair capacity

Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) (2014) Cronin K SEER Cancer Statistics Review, 1975–2011, National Cancer Institute, Bethesda, Md, USA, 2013, based on November 2013 SEER data submission, posted to the SEER web site http://seer.cancer.gov/csr/1975_2011/. Accessed 25 July 2022

Veness MJ, Porter GS, Morgan GJ (2004) Anaplastic thyroid carcinoma: dismal outcome despite current treatment approach. ANZ J Surg 74(7):559–562. https://doi.org/10.1111/j.1445-2197.2004.03062.x

Article  PubMed  Google Scholar 

Smallridge RC, Ain KB, Asaetal SL (2012) American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 22(11):1104–1139. https://doi.org/10.1089/thy.2012.0302

Article  PubMed  Google Scholar 

Busnardo B, Daniele O, Pelizzo MR, Mazzarotto R, Nacamulli D, Devido D, Mian C, Girelli ME (2000) A multimodality therapeutic approach in anaplastic thyroid carcinoma: study on 39 patients. J Endocrinol Invest 23(11):755–761. https://doi.org/10.1007/BF03345066

Article  CAS  PubMed  Google Scholar 

Haigh PI, Ituarte PH, Wu HS, Treseler PA, Posner MD, Quivey JM, Duh QY, Clark OH (2001) Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival. Cancer 91(12):2335–2342

Article  CAS  PubMed  Google Scholar 

Stavas MJ, Shinohara ET, Attia A, Ning MS, Friedman JM, Cmelak AJ (2014) Short course high dose radiotherapy in the treatment of anaplastic thyroid carcinoma. J Thyroid Res 2014:764281. https://doi.org/10.1155/2014/764281

Article  PubMed  PubMed Central  Google Scholar 

De Leo S, Trevisan M, Fugazzola L (2020) Recent advances in the management of anaplastic thyroid cancer. Thyroid Res 13(1):17. https://doi.org/10.1186/s13044-020-00091-w

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harari PM, Huang SM (2000) Modulation of molecular targets to enhance radiation. Clin Cancer Res 6(2):323–325

CAS  PubMed  Google Scholar 

Lane AA, Chabner BA (2009) Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 27(32):5459–5468. https://doi.org/10.1200/JCO.2009.22.1291

Article  CAS  PubMed  Google Scholar 

Marks PA, Xu WS (2009) Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107(4):600–608. https://doi.org/10.1002/jcb.22185

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ranganna K, Selvam C, Shivachar A, Yousefipour Z (2020) Histone deacetylase inhibitors as multitarget-directed epi-drugs in blocking PI3k oncogenic signaling: a polypharmacology approach. Int J Mol Sci 21(21):8198. https://doi.org/10.3390/ijms21218198

Article  CAS  PubMed  PubMed Central  Google Scholar 

Munster PN, Marchion D, Thomas S, Egorin M, Minton S, Springett G, Lee JH, Simon G, Chiappori A, Sullivan D, Daud A (2009) Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. Clin Trial Br J Cancer 101(7):1044–1050. https://doi.org/10.1038/sj.bjc.6605293

Article  CAS  Google Scholar 

Groselj B, Sharma NL, Hamdy FC, Kerr M, Kiltie AE (2013) Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signalling and repair. Br J Cancer 108:748–754. https://doi.org/10.1038/bjc.2013.21

Article  CAS  PubMed  PubMed Central  Google Scholar 

Moertl S, Payer S, Kell R, Winkler K, Anastasov N, Atkinson MJ (2019) Comparison of radiosensitization by HDAC Inhibitors CUDC-101 and SAHA in pancreatic cancer cells. Int J Mol Sci 20(13):3259. https://doi.org/10.3390/ijms20133259

Article  CAS  PubMed  PubMed Central  Google Scholar 

van Breemen MS, Rijsman RM, Taphoorn MJ, Walchenbach R, Zwinkels H, Vecht CJ (2009) Efficacy of anti-epileptic drugs in patients with gliomas and seizures. J Neurol 256(9):1519–1526. https://doi.org/10.1007/s00415-009-5156-9

Article  PubMed  Google Scholar 

Zhu MM, Li HL, Shi LH, Chen XP, Luo J, Zhang ZL (2017) The pharmacogenomics of valproic acid. J Hum Genet 62(12):1009–1014. https://doi.org/10.1038/jhg.2017.91

Article  CAS  PubMed  Google Scholar 

Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20(24):6969–6978. https://doi.org/10.1093/emboj/20.24.6969

Article  CAS  PubMed  PubMed Central  Google Scholar 

Blaheta RA, Michaelis M, Driever PH, Cinatl JJ (2005) Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 25:383–397. https://doi.org/10.1002/med.20027

Article  CAS  PubMed  Google Scholar 

Cinatl JJ, Cinatl J, Scholz M, Driever PH, Henrich D, Kabickova H, Vogel JU, Doerr HW, Kornhuber B (1996) Antitumor activity of sodium valproate in cultures of human neuroblastomacells. Anticancer Drugs 7:766–773. https://doi.org/10.1097/00001813-199609000-00008

Article  PubMed  Google Scholar 

Driever PH, Knüpfer MM, Cinatl J, Wolff JEA (1999) Valproic acid for the treatment of pediatric malignant glioma. Klin Padiatr 211:323–328. https://doi.org/10.1055/s-2008-1043809

Article  CAS  PubMed  Google Scholar 

Michaelis M, Doerr HW, Cinatl J (2007) Valproic acid as anti-cancer drug. Current Pharmaceut Des 13:3378–3393

Article  CAS  Google Scholar 

Catalano MG, Fortunati N, Pugliese M, Costantino L, Poli R, Bosco O, Boccuzzi G (2005) Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 90(3):1383–1389. https://doi.org/10.1210/jc.2004-1355

Article  CAS  PubMed  Google Scholar 

Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G (2004) Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 89(2):1006–1009. https://doi.org/10.1210/jc.2003-031407

Article  CAS  PubMed  Google Scholar 

Karagiannis TC, El-Osta A (2006) Modulation of cellular radiation responses by histone deacetylase inhibitors. Oncogene 25(28):3885–3893. https://doi.org/10.1038/sj.onc.1209417

Article  CAS  PubMed  Google Scholar 

Makita N, Ninomiya I, Tsukada T, Okamoto K, Harada S, Nakanuma S, Sakai S, Makino I, Kinoshita J, Hayashi H, Katsunobu O, Hisatoshi N, Tomoharu M, Hidehiro T, Hiroyuki T, Sachio F, Tetsuo O (2015) Inhibitory effects of valproic acid in DNA double-strand break repair after irradiation in esophageal squamous carcinoma cells. Oncol Rep 34(3):1185–1192. https://doi.org/10.3892/or.2015.4089

Article  CAS  PubMed  Google Scholar 

Luo Y, Wang H, Zhao XP, Dong X, Zhang FM, Guo G, Guo WXW, Powell SN, Feng ZH (2016) Valproic acid causes radiosensitivity of breast cancer cells via disrupting the DNA repair pathway. Toxicol Res (Cam) 5(3):859–870. https://doi.org/10.1039/c5tx00476d

Article  CAS  Google Scholar 

Van Oorschot B, Granata G, Franco S, Cate R, Rodermond HM, Todaro M, Medema JP, Franken NAP (2016) Targeting DNA double strand break repair with hyperthermia and DNA-PKCS inhibition to enhance the effect of radiation treatment. Oncotarget 7:65504–65513. https://doi.org/10.1863/oncotarget.11798

Article  PubMed  PubMed Central  Google Scholar 

Chinnaiyan P, Cerna D, Burgan WE, Beam K, Williams ES, Camphausen K, Tofilon PJ (2008) Postradiation sensitization of the histone deacetylase inhibitor valproic acid. Clin Cancer Res 14:5410–5415. https://doi.org/10.1158/1078-0432.CCR-08-0643

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perona M, Thomasz L, Rossich L, Rodriguez C, Pisarev MA, Rosemblit C, Cremaschi GA, Dagrosa MA, Juvenal GJ (2018) Radiosensitivity enhancement of human thyroid carcinoma cells by the inhibitors of histone deacetylase sodium butyrate and valproic acid. Mol Cell Endocrinol 478:141–150. https://doi.org/10.1016/j.mce.2018.08.007

Article  CAS  PubMed  Google Scholar 

Barker CA, Bishop AJ, Chang M, Beal K, Chan TA (2013) Valproic acid use during radiation therapy for glioblastoma associated with improved survival. Int J Radiat Oncol Biol Phys 86(3):504–509. https://doi.org/10.1016/j.ijrobp.2013.02.012

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, Tofilon PJ, Fine HA, Camphausen K (2015) A phase 2 study of concurrent radiation therapy, Temozolomide, and the histone deacetylase inhibitor valproic acid for patients with glioblastoma. Int J Radiat Oncol Biol Phys 92(5):986–992. https://doi.org/10.1016/j.ijrobp.2015.04.038

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tennvall J, Lundell G, Wahlberg P, Bergenfelz A, Grimelius L, Akerman M, Hjelm Skog AL, Wallin G (2002) Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 86(12):1848–1853. https://doi.org/10.1038/sj.bjc.6600361

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chateauvieux S, Morceau F, Dicato M, Diederich M (2010) Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010:479364. https://doi.org/10.1155/2010/479364

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noguchi H, Yamashita H, Murakami T, Hirai K, Noguchi Y, Maruta J, Yokoi T, Noguchi S (2009) Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr J 56:245–249. https://doi.org/10.1507/endocrj.k08e-016

Article  PubMed 

留言 (0)

沒有登入
gif